Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 165.46x is 41% below its estimated 1-year average of 281.64x, near the low end of its estimated 1-year range (86.80x–558.23x).
As of 2026-10-06T16:43:22.961Z.
Calculation as of: 2026-10-06T16:43:22.961Z.
Quote observation: 2026-10-06T16:37:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a8ac43d83dffe882666147bba78c75a2aa07862642b14baa2694f769a95b4c3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
165.46x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.20x
median of 492 covered companies
CURRENT VS SECTOR MEDIAN
+3839.52%
vs the sector median at left
Market Cap
$5.14M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.20M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.23M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.36M
EV/Sales Ratio
0.76x
TTM Avg
1.63x
3Y Avg
1.96x
5Y Avg
36.60x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | 165.46x | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.14M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.13M | N/A | 21.78x | 80.72x | 86.37x |
| Soligenix, Inc. (SNGX)vs › | $5.34M | N/A | 2.85x | 161.09x | 86.59x |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.36M | 0.76x | 1.63x | 1.96x | 36.60x |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | N/A | 974.76x | 727.03x | 628.61x |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-05 | 86.80x |
| 2026-10-02 | 110.67x |
| 2026-10-01 | 122.61x |
| 2026-09-30 | 136.03x |
| 2026-09-29 | 180.79x |
| 2026-09-28 | 194.21x |
| 2026-09-25 | 204.66x |
| 2026-09-24 | 206.15x |
| 2026-09-23 | 235.99x |
| 2026-09-22 | 249.41x |
| 2026-09-21 | 259.86x |
| 2026-09-18 | 264.33x |
| 2026-09-17 | 256.87x |
| 2026-09-16 | 240.46x |
| 2026-09-15 | 243.45x |
| 2026-09-14 | 240.46x |
| 2026-09-11 | 271.79x |
| 2026-09-10 | 280.74x |
| 2026-09-09 | 306.11x |
| 2026-09-08 | 304.61x |
| 2026-09-04 | 273.28x |
| 2026-09-03 | 267.32x |
| 2026-09-02 | 274.78x |
| 2026-09-01 | 237.48x |
| 2026-08-31 | 256.87x |
| 2026-08-28 | 270.30x |
| 2026-08-27 | 267.32x |
| 2026-08-26 | 274.78x |
| 2026-08-25 | 244.94x |
| 2026-08-24 | 234.50x |
| 2026-08-21 | 237.48x |
| 2026-08-20 | 244.94x |
| 2026-08-19 | 247.92x |
| 2026-08-18 | 240.46x |
| 2026-08-17 | 252.40x |
| 2026-08-14 | 247.92x |
| 2026-08-13 | 250.91x |
| 2026-08-12 | 267.32x |
| 2026-08-11 | 274.78x |
| 2026-08-10 | 268.81x |
| 2026-08-07 | 276.27x |
| 2026-08-06 | 277.76x |
| 2026-08-05 | 286.71x |
| 2026-08-04 | 297.15x |
| 2026-08-03 | 273.28x |
| 2026-07-31 | 206.15x |
| 2026-07-30 | 218.08x |
| 2026-07-29 | 231.51x |
| 2026-07-28 | 250.91x |
| 2026-07-27 | 249.41x |
| 2026-07-24 | 264.33x |
| 2026-07-23 | 262.84x |
| 2026-07-22 | 306.11x |
| 2026-07-21 | 328.48x |
| 2026-07-20 | 310.58x |
| 2026-07-17 | 337.43x |
| 2026-07-16 | 346.39x |
| 2026-07-15 | 361.30x |
| 2026-07-14 | 361.30x |
| 2026-07-13 | 338.93x |
| 2026-07-10 | 355.34x |
| 2026-07-09 | 324.01x |
| 2026-07-08 | 325.50x |
| 2026-07-07 | 337.43x |
| 2026-07-06 | 377.71x |
| 2026-07-02 | 394.13x |
| 2026-07-01 | 377.71x |
| 2026-06-30 | 404.57x |
| 2026-06-29 | 389.65x |
| 2026-06-26 | 395.62x |
| 2026-06-25 | 447.83x |
| 2026-06-24 | 428.44x |
| 2026-06-23 | 558.23x |
| 2026-06-22 | 535.85x |
| 2026-06-18 | 480.65x |
| 2026-06-17 | 513.48x |
| 2026-06-16 | 341.91x |
| 2026-06-15 | 306.11x |
| 2026-06-12 | 276.27x |
| 2026-06-11 | 289.69x |
| 2026-06-10 | 253.89x |
| 2026-06-09 | 258.37x |
| 2026-06-08 | 270.30x |
| 2026-06-05 | 282.24x |
| 2026-06-04 | 352.35x |
| 2026-06-03 | 344.89x |
| 2026-06-02 | 361.30x |
| 2026-06-01 | 358.32x |
| 2026-05-29 | 376.22x |
| 2026-05-28 | 370.26x |
| 2026-05-27 | 307.60x |
| 2026-05-26 | 231.51x |
| 2026-05-22 | 253.89x |
| 2026-05-21 | 262.84x |
| 2026-05-20 | 185.26x |
| 2026-05-19 | 215.10x |
| 2026-05-18 | 225.54x |
